The Niemann Pick C1 Protein pipeline drugs market research report outlays comprehensive information on the Niemann Pick C1 Protein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Niemann Pick C1 Protein pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Metabolic Disorders, and Infectious Disease which include the indications Niemann-Pick Disease Type C, and Ebolavirus Infections (Ebola Hemorrhagic Fever). It also reviews key players involved in Niemann Pick C1 Protein targeted therapeutics development with respective active and dormant or discontinued products.
The Niemann Pick C1 Protein pipeline targets constitutes close to seven molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Preclinical, and Discovery stages are 4, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Niemann Pick C1 Protein overview
Niemann-Pick C1 protein (NPC1) is a transmembrane glycoprotein that plays a crucial role in the regulation of cholesterol and other lipids within cells. Mutations in the NPC1 gene can lead to Niemann-Pick disease type C (NPC), a rare and inherited lysosomal storage disorder. The main function of NPC1 is to facilitate the transport of cholesterol from the endolysosomal system to other cellular compartments. It acts in conjunction with another protein called NPC2 to mediate the egress of cholesterol from lysosomes.
For a complete picture of Niemann Pick C1 Protein’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
